BioDelivery Sciences (NASDAQ:BDSI) shareholders got some welcome good news today, with positive phase 3 top-line data for BEMA buprenorphine sending shares up 9% as of this writing.

The drug provided a statistically significant improvment in chronic pain relief versus placebo, and the trial's completion triggered a $10 million payment from commercialization partner Endo International (NASDAQ:ENDP). So, considering today's good news, should investors think about buying BioDelivery stock?

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give more details on the drug and whether this makes BioDelivery Sciences a stock to buy.

David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.